id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-030923-r0lfot3w	Liu, Lixin	Subunit Nanovaccine with Potent Cellular and Mucosal Immunity for COVID-19	2020-08-18		.txt	text/plain	3704	221	57	[Image: see text] To combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, we formulated the S1 subunit of the virus with two adjuvants, amphiphilic adjuvant monophosphoryl lipid A for Toll-like receptor 4 and CpG oligodeoxynucleotide for Toll-like receptor 9, into cationic liposomes to produce a potent, safer, and translatable nanovaccine. NANOVACCINE MPLA/CpG-loaded liposome particle, p(M+C), was produced via a thin-film hydration approach by using cationic 1,2dioleoyl-3-trimethylammonium-propane (DOTAP), helper lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and cholesterol as carrier materials. Previous research on vaccines using the spike protein of severe acute respiratory syndrome coronavirus (SARS-CoV) as the subunit showed that the antibodies could effectively prevent the coronavirus from binding to the cell and undergoing membrane fusion, neutralizing the virus during infection. Moreover, MPLA/CpG-loaded liposomes alone can be used as nanoparticulate adjuvants of a coronavirus vaccine with different antigens to enhance an innate immunity and thus a cellular immune response.	./cache/cord-030923-r0lfot3w.txt	./txt/cord-030923-r0lfot3w.txt